Sutro Biopharma Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
128
- Stock Symbol
-
STRO
- Investments
-
1
- Share Price
-
$9.80
- (As of Friday Closing)
Sutro Biopharma General Information
Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Contact Information
Website
www.sutrobio.comCorporate Office
- 111 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 111 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Sutro Biopharma Stock Performance
As of 13-Nov-2026, Sutro Biopharma’s stock price is $9.80. Its current market cap is $163M with 16.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.80 | $9.59 | $7.15 - $43.85 | $163M | 16.6M | 308K | -$12.49 |
Sutro Biopharma Financials Summary
As of 30-Sep-2026, Sutro Biopharma has a trailing 12-month revenue of $45.1M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 113,560 | (51,364) | (211,666) | (55,487) |
| Revenue | 45,107 | 102,484 | 62,043 | 153,731 |
| EBITDA | (114,141) | (151,043) | (231,235) | (72,545) |
| Net Income | (155,268) | (191,086) | (227,461) | (106,793) |
| Total Assets | 176,648 | 173,830 | 387,207 | 470,736 |
| Total Debt | 9,700 | 15,674 | 23,154 | 33,635 |
Sutro Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sutro Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sutro Biopharma Comparisons
Industry
Financing
Details
Sutro Biopharma Competitors (116)
One of Sutro Biopharma’s 116 competitors is Mersana Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA |
Sutro Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sutro Biopharma Patents
Sutro Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236501-A1 | Anti-avb6 antibodies, compositions comprising anti-avb6 antibodies and methods of making and using anti-avb6 antibodies | Pending | 07-May-2025 | ||
| WO-2026236446-A1 | Anti-αvβ6 antibody conjugates, compositions comprising anti- αvβ6 antibody conjugates and methods of making and using anti-αvβ6 antibody conjugates | Pending | 07-May-2025 | ||
| WO-2026182895-A1 | Process of making cell extract | Pending | 25-Feb-2025 | ||
| WO-2026165269-A1 | Anti-b7-h3 antibodies, compositions comprising anti-b7-h3 antibodies and methods of making and using anti- b7-h3 antibodies | Pending | 29-Jan-2025 | ||
| WO-2026136953-A2 | High cell density fed-batch fermentation | Pending | 20-Dec-2024 | C12N1/06 |
Sutro Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sutro Biopharma Investments (1)
Sutro Biopharma’s most recent deal was a Early Stage VC with Vaxcyte for . The deal was made on 23-Jul-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vaxcyte | 23-Jul-2015 | Early Stage VC | Drug Discovery |
Sutro Biopharma ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
33.48 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Sutro Biopharma Exits (1)
Sutro Biopharma’s most recent exit was on 23-Jul-2015 from Vaxcyte. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Vaxcyte | 23-Jul-2015 | Completed |
|
Sutro Biopharma FAQs
-
When was Sutro Biopharma founded?
Sutro Biopharma was founded in 2003.
-
Where is Sutro Biopharma headquartered?
Sutro Biopharma is headquartered in South San Francisco, CA.
-
What is the size of Sutro Biopharma?
Sutro Biopharma has 128 total employees.
-
What industry is Sutro Biopharma in?
Sutro Biopharma’s primary industry is Drug Delivery.
-
Is Sutro Biopharma a private or public company?
Sutro Biopharma is a Public company.
-
What is Sutro Biopharma’s stock symbol?
The ticker symbol for Sutro Biopharma is STRO.
-
What is the current stock price of Sutro Biopharma?
As of 13-Nov-2026 the stock price of Sutro Biopharma is $9.80.
-
What is the current market cap of Sutro Biopharma?
The current market capitalization of Sutro Biopharma is $163M.
-
What is Sutro Biopharma’s current revenue?
The trailing twelve month revenue for Sutro Biopharma is $45.1M.
-
Who are Sutro Biopharma’s competitors?
Mersana Therapeutics, Inhibrx, Fate Therapeutics, Arcus Biosciences, and Iovance Biotherapeutics are some of the 116 competitors of Sutro Biopharma.
-
What is Sutro Biopharma’s annual earnings per share (EPS)?
Sutro Biopharma’s EPS for 12 months was -$12.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
